Conversations on 
Twitter :
 |
|
|
|
@FierceBiotech: Add a drop of blood, and this tiny Dx device tests 50 things at once. Story | Follow @FierceBiotech
@JohnCFierce: Halozyme gets $8M upfront and a bunch of potential biobucks in drug delivery collab with Pfizer. Release | Follow @JohnCFierce
@RyanMFierce: Halozyme rebounds with $8M Pfizer biologics pact. More | Follow @RyanMFierce
> An FDA advisory panel voted 8-5 against a drug from Hemispherix Biopharma ($HEB) for treating chronic fatigue syndrome. Article
> Irish pharma company Elan ($ELN) has wrapped the demerger of its drug discovery business into a new company called Prothena. Release
> Cubist ($CBST) submitted a supplemental NDA for approval of Entereg for use in speeding GI recovery after bowel surgeries. Release
> Bloomberg reported on treatments for autism that might border on fraud. Item
Pharma News
@FiercePharma: Smaller players looking for expansion deals, too. News | Follow @FiercePharma
> Sanofi animal health deal puts it in India. More
> India vaccinemakers see China undercutting them. Story
> EMA having second thoughts about Merck's Tredaptive. Item
@FierceMedDev: St. Jude faces escalation of shareholder lawsuits over Durata leads. Article | Follow @FierceMedDev
@MarkHFierce: Nanostim says it successfully implanted leadless cardiac pacers into 11 patients in the Czech Republic. Major progress. News | Follow @MarkHFierce
@DamianFierce: Critical Diagnostics has inked distribution deals for its heart test with Quest ($DGX) and LabCorp ($LH). More | Follow @DamianFierce
> Invacare unloads med supplies unit to AssuraMed for $150M. Story
> Cincinnati Children's/Ben-Gurion U back three pediatric device projects. Item
> Illumina soars on fresh Roche buyout rumors. Report
And Finally… Happy holidays! We'll resume breaking news coverage on Dec. 26 and send your next issue of FierceBiotech on Jan. 2.